Shots:
- The CHMP has recommended Sanofi‘s Cenrifki for the treatment of SPMS without relapses in the last 2yrs.; regulatory submissions are ongoing in other regions
- Opinion was backed by P-III (HERCULES) trial in non-relapsing SPMS & supporting data from P-III (GEMINI 1 & 2) studies in relapsing multiple sclerosis, with HERCULES demonstrating delayed onset of disability progression
- Cenrifki is an oral, brain-penetrant BTK inhibitor designed to target smoldering neuroinflammation for delaying disability progression in multiple sclerosis
Ref: Sanofi | Image: Sanofi |Press Release
Related News: Regeneron and Sanofi Report the US FDA Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
